Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

Core Insights - Lifecore Biomedical, Inc. has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical customer, marking a significant step in its commercial strategy [1][4] - The agreements are expected to contribute to Lifecore's commercial revenue by 2028, reflecting the company's focus on high-value, late-stage pipeline programs [1][4][8] Agreement Details - The first agreement involves a commercial site transfer for a currently marketed product that will now be manufactured by Lifecore, which includes technical transfer services and process performance qualification batches at commercial scale [2] - The second agreement expands Lifecore's services for a product used in treating ophthalmic-related diseases, allowing the company to manufacture it in a new delivery system that is currently produced in Europe [3] Company Positioning - The recent agreements highlight Lifecore's growing reputation as a partner-of-choice among commercial customers, driven by its commitment to customer service, quality standards, and technical expertise [5] - The signing of these agreements during DCAT week underscores Lifecore's successful new commercial strategy and its prioritization of transfer programs, which have a higher probability of approval compared to earlier stage development programs [4][5] Company Overview - Lifecore Biomedical is a fully integrated CDMO specializing in the development, fill, and finish of sterile injectable pharmaceutical products, with over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid [6]